Spain
Pharmamel Drug Discovery, headquartered in Spain, is a promising R&D biotech spin-off from the University of Granada formed in 2014. The company's mission is encapsulated in its slogan: "Development of new drugs for inflammatory diseases by putting melatonin at the service of biotechnology."
Pharmamel's lead product focuses on an intravenous melatonin injectable to treat sepsis, a life-threatening condition that's the leading cause of hospital deaths worldwide. Backed by critical technology licenses from the Andalusian Health Service and the University of Granada, the company has completed two Phase II clinical trials, confirming both the safety and efficacy of their drug candidate.
The company's strategic positioning within the Biotechnology and Pharmaceutical industries, combined with tangible clinical success, presents a compelling opportunity for investors. Notable is the absence of recent investments, leaving the door open for investors ready to capitalize on a high-potential venture within the transformative realm of biomedical R&D.
